Leerink Partners initiates coverage on Aduro Biotech (NASDAQ: ADRO) with a Outperform rating and a price target of $48.00.Analyst Howard ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE